PubMed Health⌕ Search

PubMed · 7928503

Tissue heterogeneity effects in treatment plan optimization.

Abstract

PURPOSE: There is general agreement that tissue density correction factors improve the accuracy of dose calculations. However, there is disagreement over the proper heterogeneity correction algorithm and a lack of clinical experience in using them. Therefore, there has not been widespread implementation of density correction factors into clinical practice. Furthermore, the introduction of optimized conformal therapy leads to new and radically different treatment techniques outside the clinical experience of the physician. It is essential that the effects of tissue density corrections are understood so that these types of treatments can be safely delivered. METHODS AND MATERIALS: In this paper, we investigate the effect of tissue density corrections on optimized conformal type treatment planning in the thorax region. Specifically, we study the effects on treatment plans optimized without type treatment planning in the thorax region. Specifically, we study the effects on treatment plans optimized without tissue density corrections, when those corrections are applied to the resulting dose distributions. These effects are compared for two different conformal techniques. RESULTS: This study indicates that failure to include tissue density correction factors results in an increased dose of approximately 5-15%. This is consistent with published studies using conventional treatment techniques. Additionally, the high-dose region of the dose distribution expands laterally into the uninvolved lung and other normal structures. The use of dose-volume histograms to compare these distributions demonstrates that treatment plans optimized without tissue density corrections lead to an increased dose to uninvolved normal structures. This increase in dose often violates the constraints used to determine the optimal solution. CONCLUSIONS: The neglect of tissue density correction factors can result in a 5-15% increase in the delivered dose. In addition, suboptimal dose distributions are produced. To benefit from the advantages of optimized conformal therapy in the thorax, tissue density correction factors should be used.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S M Morrill, M L Langer, R G Lane, I I Rosen. 1994-10-15. Tissue heterogeneity effects in treatment plan optimization.. https://doi.org/10.1016/0360-3016(92)90958-k

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Gastric amphicrine carcinoma in the stomach: an unexpected presentation of MUTYH-associated polyposis.

Amphicrine carcinomas of the stomach, defined by dual exocrine and neuroendocrine differentiation within the same neoplastic cell, are exceedingly rare. MUTYH-associated polyposis (MAP) is an autosomal recessive polyposis syndrome characterized by multiple colorectal adenomas and variable upper gastrointestinal involvement; however, amphicrine carcinomas have not been previously documented in this setting. We report a gastric amphicrine carcinoma arising in the background of extensive fundic gland polyposis in a patient with MAP. Endoscopy revealed a 3.5-cm flat elevated lesion in the gastric fundus amid extensive fundic gland polyposis. Histologically, the tumor consisted of a single population of cells exhibiting combined glandular and neuroendocrine differentiation without zonal or biphasic architecture, and many of these cells demonstrated true amphicrine morphology. Immunohistochemistry confirmed co-expression of cytokeratin and the neuroendocrine markers chromogranin A and synaptophysin in the same cell population. Germline targeted next-generation sequencing identified biallelic MUTYH variants in trans (c.733C>T, p.Arg245Cys [likely pathogenic]; c.842C>T, p.Ala281Val [variant of uncertain significance]), supporting a diagnosis of MAP. To our knowledge, this is the first reported case of a gastric amphicrine carcinoma in a MAP patient, expanding the spectrum of MAP-associated upper gastrointestinal neoplasia and underscoring the importance of vigilant endoscopic surveillance in hereditary polyposis syndromes.

Carcinoma↗

Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database.

BACKGROUND: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has expanded its application in the management of peritoneal carcinomatosis from gastrointestinal and ovarian malignancies. An accurate assessment of perioperative outcomes is crucial for integration of this combined procedure into clinical practice. METHODS: A prospective study of 80 patients undergoing the combined treatment for non-appendiceal peritoneal carcinomatosis was conducted. Forty-seven adverse events by eight organ-systems were rated from Grade I to IV with increasing severity. RESULTS: One patient (1.3%) died postoperatively. Postoperative adverse events affected genitourinary system (38%), hematological system (31%), gastrointestinal system (25%), infection (20%), intravenous catheters status (15%), pulmonary system (14%), cardiovascular system (11%) and neurological system (4%). Thirty-six patients (45%) experienced 49 Grade III adverse events. Six patients (8%) experienced eight Grade IV adverse events. More than four peritonectomy procedures (P = 0.010), and length of hospital stay of more than 21 days (P = 0.007) were strongly associated with Grade III and/or Grade IV morbidity. CONCLUSION: The morbidity and mortality rates after the combined treatment for non-appendiceal peritoneal carcinomatosis were within the acceptable range of surgical treatments for other gastrointestinal cancers. A standardized prospective database is required for an accurate assessment of perioperative outcomes.

Carcinoma↗

Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975-2004.

We studied the possible relationship among parity, female sterilization, hysterectomy and the risk of primary fallopian tube carcinoma (PFTC) in a case-control study in Finland in cases occurring between 1975 and 2004. A total of 573 PFTC cases were identified from the Finnish Cancer Registry, and 10 age-matched controls per case were randomly selected from the Finnish Central Population Registry. In multivariate analysis (including 189 PFTC cases and 1764 controls) parity was protective: the odds ratio (OR) for 1-2 deliveries was 0.63 (95% CI 0.44-0.91) and for > or =3 deliveries, 0.32 (95% CI 0.19-0.52). The OR for sterilization was 0.74 (95% CI 0.42-1.30) and for hysterectomy 1.27 (95% CI 0.73-2.21). Our findings suggest a possible hormonal background as regards the development of PFTC.

Carcinoma↗